Pembrolizumab,lenvatinib,nivolumab,E7386
Merck,Eisai,bms,
[]
#eisai aims to advance #gastrointestinalcancer treatment with research across multiple tumor types at #ascogi23 
Follow top-line development in the oncology commercial domain through our award winning intelligence service, 1stOncology.